Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases

Summary

This is a single arm, phase II study without blinding. The purpose is to determine the impact of hepatic artery infusion Floxuridine (FUDR) on liver metastases from pancreatic adenocarcinoma. Patients at Spectrum Health will receive standard of care chemotherapy. They will also receive chemotherapy via surgically placed hepatic artery infusion (HAI) pump.

Timeline

Start

2019-02-05

Primary completion

2028-12

Completion

2028-12

Drugs

Indications